Метаболические нарушения функции печени у больных с ожирением в контексте инфекции COVID-19

Татьяна Гельмич; Юлианна Лупашко; Влада-Татьяна Думбрава; Даниелла Лупашко; Татьяна Бурда; Марианна Оуш-Чеботарь

Metabolic disturbances of liver function in patients with obesity in the context of COVID-19 infection

Autori

Tatiana Ghelimici Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“ https://orcid.org/0000-0001-6566-2943
Iulianna Lupasco Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“ https://orcid.org/0000-0002-1282-5080
Vlada-Tatiana Dumbrava Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“ https://orcid.org/0000-0002-6866-1070
Daniella Lupasco Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“ https://orcid.org/0000-0003-1876-6322
Tatiana Burda Spitalul Clinic Republican „Timofey Moshnyaga” https://orcid.org/0000-0002-1274-4002
Mariana Ous-Cebotar Spitalul Clinic Republican „Timofey Moshnyaga” https://orcid.org/0009-0005-0112-0404

Cuvinte cheie:

infecție cu virus COVID-19, obezitate, IMC, sindrom de citoliză, metabolism proteic, albumină, feritină, proteina C reactivă

Rezumat

The COVID-19 pandemic and its consequences present a serious threat to the life and health of people, leading to high morbidity, disability and mortality. Obesity and other components of the metabolic syndrome may worsen the course of COVID-19 infection and the functional state of the hepatobiliary system. Purpose of study was the study of biochemical parameters characterizing the syndrome of cytolysis and protein metabolism in obese patients with SARS CoV-2 viral infection. We examined 44 patients: 27 men (61.62%), 17 women (38.6%). The mean age was 55.16 ± 4.5 years. The patients were divided into 4 groups: group 1 (9) consisted of patients with a body mass index (BMI) of 30, group 2 (8) with a BMI of 35, group 3 with a BMI of 40, group 4 of the comparison (CG) consisted of patients (17) with no signs of obesity. In all patients, cytolysis syndrome (ALAT, ASAT) and protein metabolism: ferritin (FT), serum albumin and C-reactive protein (CRP) were studied. The study revealed an increase in the ALAT, ASAT, FT and CRP levels in patients with a high body mass index against the background of a serum albumin decrease. All patients with COVID-19 viral infection and obesity showed changes in the parameters of cytolysis syndrome and protein metabolism. Patients with COVID-19 viral infection and obesity constitute a high-risk group and require constant preventive and diagnostic monitoring by gastroenterologists and endocrinologists.

Referințe

1. Banchini, F., Cattaneo, G.M., Capelli, P. Serum ferritin levels in inflammation: a retrospective comparative analysis between COVID-19 and emergency surgical non-COVID-19 patients. In: World J Emerg Surg. 2021; 16:9. https://doi.org/10.1186/s13017-021-00354-3

2. Baral, R., Ali, O., Brett, I., Reinhold, J., Vassiliou, V.S. COVID-19: a pan-organ pandemic. In: Oxf Med Case Reports. 2020. https://doi.org/10.1093/omcr/omaa107

3. Beyerstedt, S., Casaro, E.B., Rangel, É.B. COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection. In: Eur J ClinMicrobiol Infect Dis. 2021; 40, pp. 905-919. https://doi.org/10.1007/s10096-020-04138-6

4. Black, S., Kushner, I., Samols, D. C-reactive protein. In: JBiol Chem. 2004; 279(47), pp. 48487-48490. https://doi.org/10.1074/jbc.R400025200

5. Booth, A., Magnuson, A., Fouts, J., Foster, M.T. Adipose tissue: an endocrine organ playing a role in metabolic regulation. In: HormMolBiolClin Invest. 2016; 26(1), pp. 25-42. https://doi.org/10.1515/hmbci-2015-0073

6. Chen, J., Chen, J., Fu, H., Li, Y., Wang, L., Luo, S., Lu, H. Hypoxia exacerbates nonalcoholic fatty liver disease via the HIF-2α/PPARα pathway. In: Am J PhysiolEndocrinolMetab.2019; 317, pp. E710-E722. https://doi.org/10.1152/ajpendo.00052.2019

7. Chen, L., Liu, H.G., Liu, W., Liu, J., Liu, K., Shang, J. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. In: ZhonghuaJie He He Hu Xi ZaZhi. 2020; 43(3), pp. 203-208.

8. Cheung, K.S., Hung, I.F.N., Chan, P.P.Y., Lung, K.C., et al. Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from the Hong Kong cohort and systematic review and metaanalysis. In: Gastroenterology. 2020; 159(1), pp. 81-95. https://doi.org/10.1053/j.gastro.2020.03.065

9. Chinazzi, M., Davis, J.T., Ajelli, M., Gioannini, C., Litvinova, M., Merler, S., et al. The effect of travel restrictions on the spread of the 2019 novel coronavirus (COVID-19) outbreak. In: Science. 2020; 368(6489), pp. 395-400. https://doi.org/10.1126/science.aba9757

10. Curocichin, Gh., Șalaru, V., Gîțu, L. Protocolul clinic standardizet pentru medicii de familie. Infecția cu coronavirus de tip nou COVID-19. Pentru aplicare în cazul de sfășurării Scenariului 3 din Planul de pregătire și răspuns, la infecţia cu coronavirus de tip nou COVID-19. Chișinău, 2020; 6 p.

11. Da, BL., Mitchell, RA., Lee, BT., et al. Kinetic patterns of liver enzyme elevation with COVID-19 in the USA. In: Eur. GastroenterolHepatol. 2020; 32(11), pp. 1466-1469. https://doi.org/10.1097/MEG.0000000000001792

12. Dalan, R., Bornstein, S.R., El-Armouche, A., Rodionov, R.N., Markov, A., Wielockx, B. The ACE-2 in COVID-19: foe or friend? In: HormMetab Res. 2020; 52(5), pp. 257-263. https://doi.org/10.1055/a-1155-0501

13. Di Angelantonio, E., Bhupathiraju, Sh. N., Wormser, D., Gao, P., Kaptoge, S., et al. Global BMIMC, Body-mass index and all-cause mortality: individual-participantdata meta-analysis of 239 prospective studies in four continents. In: Lancet. 2016; 388, pp. 776-786.

14. Garcia, L.F. Immune response, inflammation, and the clinical Spectrum of COVID-19. In: Front Immunol. 2020; 11, pp. 1441. https://doi.org/10.3389/fimmu.2020.01441

15. Gupte, M., Thatcher, S.E., Boustany-Kari, C.M. et al Angiotensin converting enzyme 2 contributes to sex differences in the development of obesity hypertension in C57BL/6 mice. In: ArteriosclerThrombVascBiol .2012 32, pp. 1392-1399. https://doi.org/10.1161/ATVBAHA.112.248559

16. Hamid. S, Alvares da Silva, M.R., Burak, K.W., Chen, T, Drenth, J.P.H., Esmat, G., Gaspar, R., La Brecque, D., Lee, A. , Macedo, G., McMahon, B., Ning, Q., Reau, N., Sonderup, M., van Leeuwen, DJ., Armstrong, D., Yurdaydin, C. WGO guidance for the care of patients with covid-19 and liver disease. In: J ClinGastroenterol. 2021; 55, pp.1-11. https://doi.org/10.1097/MCG.0000000000001459

17. Huang, W., Li, C., Wang, Z., et al. Decreased serum albumin level indicates poor prognosis of Covid-19 patients: hepatic injury analysis from 2623 hospitalized cases. In:Sci China Life Sci. 2020; 63(11), pp. 1678-1687. https://doi.org/10.1007/s11427-020-1733-4

18. Lefere, S., Tacke, F. Macrophages in obesity and nonalcoholic fatty liver disease: Crosstalk with metabolism. In: JHEP Rep.2019; 1, pp. 30-43. https://doi.org/10.1016/j.jhepr.2019.02.004

19. Li, R., Liangm M., Diang, J. Liver injury in COVID-19 patients with metabolic syndrome a narrative rewiew. In: Ann Paliliat Med 2021; 10(7), pp. 8264-8270. https://doi.org/10.21037/apm-21-1398

20. Liu, R., Nikolajczyk, B.S. Tissue immune cells fuel obesity-associated inflammation in adipose tissue and beyond. In: Front Immunol. 2019; 10, pp. 1587. https://doi.org/10.3389/fimmu.2019.01587

21. Lupasko I., Ghelmici T., Berezovscaia E., Golovatiuc L., Bugor K., Burda T. Assessment of Liver Function in SARS-CoV-2 Viral Infection. In: report during the Conference 3 Eurasian Conference The Coronovirus Pandemic; Diagnosis, Treatment 27-28 April. 2022 Bacu.

22. Lupașco, I., Tcaciuc, E., Dumbrava, V.-T., Vengher, I., Taran, N., Berezovscaia, E. Ghid de conduită a pacienților cu boli crоnice difuze hepatice în condiții de pandemie cu Covid-19. Edițiaa II-a. Chișinău: CEP Medicina, 2022; 130 p. ISBN 978-9975-82-243-5.

23. Mehta, P., Cron, R.Q., Hartwell, J., Manson, J.J., Tattersall, R.S. Silencing the cytokine storm: the use of intravenous anakinra in haemophagocyticlymphohistiocytosis or macrophage activation syndrome. In: Lancet Rheumatol. 2020; 2, pp. e358-367. https://doi.org/10.1016/S2665-9913(20)30096-5

24. Mehta, P., McAuley, D.F., Brown, M., et al. COVID-19: consider cytokine storm syndromes and immunosuppression. In: Lancet. 2020; Mar.28, 395(10229), pp. 1033-1034. https://doi.org/10.1016/S0140-6736(20)30628-0

25. Mostaghim, A., Sinha, P., Bielick, C. et al Clinical outcomes and inflammatory marker levels in patients with COVID-19 and obesity at an inner-city safety net hospital. In: PLoS ONE, 2020; nr. 15, e0243888. https://doi.org/10.1371/journal.pone.0243888

26. Petrilli, C.M., Jones, S.A., Yang, J., Rajagopalan, H., O'Donnell, L., Chernyak, Y., Tobin, K.A., Cerfolio, R.J., Francois, F., Horwitz, L.I. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. In: BMJ. 2020; 369, m1966. https://doi.org/10.1136/bmj.m1966

27. Plays, M., Müller, S., Rodriguez, R. Chemistry and biology of ferritin. In: Metallomics. 2021. https://doi.org/10.1093/mtomcs/mfab021

28. Rajgor, D.D., Lee, M.H., Archuleta, S., Bagdasarian, N., Quek, S.C. The many estimates of the COVID-19 case fatality rate. In: Lancet Infect Dis. 2020; 20(7), pp. 776-777. https://doi.org/10.1016/S1473-3099(20)30244-9

29. Richardson, S., Hirsch, J.S., Narasimhan, M., Crawford, JM., McGinn, T., Davidson, K.W., et al. Present ing characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. In: JAMA. 2020; 323(20), pp. 2052-2059. https://doi.org/10.1001/jama.2020.6775

30. Ryan, P.M., Caplice, N.M. Is adipose tissue a reservoir for viral spread, immune activation, and cytokine amplification in Coronavirus disease 2019; In: Obesity.2020; nr. 28, pp. 1191-1194. https://doi.org/10.1002/oby.22843

31. Sachdeva, S., Khandait, H., Kopel, J., Aloysius, M.M., Desai, R., Goyal, H. NAFLD and COVID-19: a Pooled Analysis. In: ComprClin Med. 2020; pp.1-4. https://doi.org/10.1007/s42399-020-00631-3

32. Sajjad, V-S., Jalil, AT., Abdelbasset, WK.,Yumashev, A.V, Karpisheh, V., Jalali, P., Adibfar, S., Ahmadi, M., Feizi, A.A.H., Jadidi-Niaragh, F. Targeting Wee1 kinase as a therapeutic approach in Hematological Malignancies. In: DNA Repair. 2021.

33. Sattar, N., McInnes, I.B., McMurray, J.J.V. Obesity a risk factor for severe COVID-19 infection: multiple potential mechanisms. In: Circulation. 2020; 142(1), pp. 4-6. https://doi.org/10.1161/CIRCULATIONAHA.120.047659

34. Schipper, H.S., Prakken, B., Kalkhoven, E., Boes, M. Adipose tissue-resident immune cells: key players in immunometabolism. In: Trends EndocrinolMetab. 2012; nr. 23(8), pp. 407-415. https://doi.org/10.1016/j.tem.2012.05.011

35. Simonnet, A., Chetboun, M., Poissy, J., Raverdy, V., Noulette, J., Duhamel, A. et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. In: Obesity. 2020; nr. 28, pp.1195-1199. 36. Sudhakar, M., Silambanan, S., Chandran, A.S., et al. C - Reactive Protein (CRP) and leptin receptor in obesity: binding of monomeric CRP to leptin receptor. In: Front Immunol .2018; nr.9, pp. 1167. https://doi.org/10.1002/oby.22831

37. Vaughan, C.J., Cronin, H., Ryan, P.M., Caplice, N.M. Obesity and COVID-19: a Virchow's triad for the 21st century. In: ThrombHaemost. 2020; nr. 120(11), pp.1590-1593. 38. WHO. Obesity and Overweight. 2018. https://doi.org/10.1055/s-0040-1714216

39. Williamson, E.J., Walker, A.J., Bhaskaran, K., et al Factors associated with COVID-19-related death using OpenSAFELY. In: Nature. 2020; 584, pp. 430-436. https://doi.org/10.1038/s41586-020-2521-4

40. Xu,Y., Yang, H., Wang, J., Li, X, Xue, C., Niu, C. and Liao, P. Serum albumin levels are a predictor of COVID-19 patient prognosis: evidence from a single cohort in Chongqing, China. In: International Journal of General Medicine. 2021; nr. 14, pp. 2785-2797. https://doi.org/10.2147/IJGM.S312521

41. Xu, L., Liu, J., Lu, M., Yang, D., Zheng, X. Liver injury during highly pathogenic human coronavirus infections. In: Liver Int. 2020; nr. 40, pp. 998-1004. https://doi.org/10.1111/liv.14435

42. Zhang, Y., Zheng, L., Liu, L., Zhao, M., Xiao, J., Zhao, Q. Liver impairment in COVID-19 patients: A retrospective analysis of 115 cases from a single centre in Wuhan city, China. In: Liver Int. 2020; nr. 40, pp. 2095-2103. https://doi.org/10.1111/liv.14455

43. Zheng, K.I., Gao, F., Wang X.B., Sun, Q.F., Pan K.H., Wang, T.Y., et al. Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease. In: Metabolism.2020; nr. 108, 154244. https://doi.org/10.1016/j.metabol.2020.154244

Descărcări

Publicat

04.05.2026

Număr

Nr. 2(93) (2022): Supliment. Zilele Medicale ale Spitalului Clinic Municipal „Sfântul Arhanghel Mihail”

Secțiune

Articole

Licență

Această lucrare este licențiată în temeiul Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Cum cităm

[1]

Ghelimici, T. et al. 2026. Metabolic disturbances of liver function in patients with obesity in the context of COVID-19 infection. Public Health Economy and Management in Medicine. 2(93) (May 2026), 277–283.